Based on the close and good cooperative relationship between Shanghai Runda Medical Technology Co., Ltd. (CACLP Booth NO.: A2-1701) and Ortho-Clinical Diagnostics (CACLP Booth NO.: A2-1701) for many years, in order to speed up the launch of Ortho related IVD equipment and reagents in Chinese market, the two parties have reached a deep strategic partnership.

On August 2, 2022, Runda Medical released a progress announcement on the signing of the "Strategic Cooperation and Joint Venture Agreement" between its wholly-owned subsidiary Shanghai Huizhong Biotechnology Co., Ltd. and Ortho Biotechnology Development (Shanghai) Co., Ltd.

The announcement stated that the joint venture between the two parties has obtained the "Business License" issued by the local market supervision administration on July 29, 2022.

Company: Shanghai Ortho Runda Biotechnology Co., Ltd.

Uniform social credit code: 91310116MABTDRP666

Type: limited liability company (foreign-invested enterprise and domestic-funded joint venture)

Legal representative: Liu Hui
Date of establishment: July 29, 2022

Registered capital: 2 million yuan (both parties account for 50% of the registered capital)

Runda Medical is one of the earliest partners of Ortho in Chinese market, and the two parties have maintained a close and good cooperative relationship for many years.

In November 2019, Ortho signed a memorandum of strategic cooperation with Huizhong Bio, a wholly-owned subsidiary of Runda Medical. This cooperation is the first in-depth strategic cooperation between Ortho and local IVD partners in Chinese market on the research and development verification before the launch of new products and the co-construction of reference laboratories.

In May 2021, Ortho Biotechnology Innovation Center was unveiled in Shanghai, and Hu Zhenning, Deputy General Manager of Runda Medical, attended as a special guest. He and many leaders and guests witnessed Ortho's comprehensive opening of localized innovation and new chapter of helping China's creation to go global.

photo of the leaders of the Ortho Biotechnology Innovation Center

From left: Deputy Director Dai Qian, Director Chen Yaobin, General Manager Yu Yong, Chairman Liu Hong, Deputy Director Chen Yanfeng, President Lin Yan, Professor Cai Kui, Professor Song Haibo, Professor Wang Hualiang

The newly established joint venture company "Ortho Runda" will develop IVD reagent products that meet the needs of the Chinese market for Ortho VITROS immunodiagnostic analyzers (including but not limited to Ortho VITROS 3600, 5600 and 7600 instruments). All intellectual property rights in any form formed during the research and development process belong to the joint venture company. At the same time, the company will provide its own production capacity and promotion channels to meet the needs of the joint venture's entrusted production and promotion.